• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Immunol . Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum

tetano

Editor, Senior Moderator
Nat Immunol


. 2020 Nov 5.
doi: 10.1038/s41590-020-00826-9. Online ahead of print.
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum


Stuart P Weisberg[SUP] 1 [/SUP], Thomas J Connors[SUP] 2 [/SUP], Yun Zhu[SUP] 2 3 [/SUP], Matthew R Baldwin[SUP] 4 [/SUP], Wen-Hsuan Lin[SUP] 1 [/SUP], Sandeep Wontakal[SUP] 1 [/SUP], Peter A Szabo[SUP] 5 [/SUP], Steven B Wells[SUP] 6 [/SUP], Pranay Dogra[SUP] 5 [/SUP], Joshua Gray[SUP] 5 [/SUP], Emma Idzikowski[SUP] 2 [/SUP], Debora Stelitano[SUP] 2 3 7 [/SUP], Francesca T Bovier[SUP] 2 3 7 [/SUP], Julia Davis-Porada[SUP] 8 [/SUP], Rei Matsumoto[SUP] 5 9 [/SUP], Maya Meimei Li Poon[SUP] 5 [/SUP], Michael Chait[SUP] 1 5 [/SUP], Cyrille Mathieu[SUP] 10 [/SUP], Branka Horvat[SUP] 10 [/SUP], Didier Decimo[SUP] 10 [/SUP], Krystalyn E Hudson[SUP] 1 [/SUP], Flavia Dei Zotti[SUP] 1 [/SUP], Zachary C Bitan[SUP] 1 [/SUP], Francesca La Carpia[SUP] 1 [/SUP], Stephen A Ferrara[SUP] 11 [/SUP], Emily Mace[SUP] 2 [/SUP], Joshua Milner[SUP] 2 [/SUP], Anne Moscona[SUP] 2 3 12 13 [/SUP], Eldad Hod[SUP] 1 [/SUP], Matteo Porotto[SUP] 14 15 16 [/SUP], Donna L Farber[SUP] 17 18 19 [/SUP]



Affiliations

Abstract

Clinical manifestations of COVID-19 caused by the new coronavirus SARS-CoV-2 are associated with age[SUP]1,2[/SUP]. Adults develop respiratory symptoms, which can progress to acute respiratory distress syndrome (ARDS) in the most severe form, while children are largely spared from respiratory illness but can develop a life-threatening multisystem inflammatory syndrome (MIS-C)[SUP]3-5[/SUP]. Here, we show distinct antibody responses in children and adults after SARS-CoV-2 infection. Adult COVID-19 cohorts had anti-spike (S) IgG, IgM and IgA antibodies, as well as anti-nucleocapsid (N) IgG antibody, while children with and without MIS-C had reduced breadth of anti-SARS-CoV-2-specific antibodies, predominantly generating IgG antibodies specific for the S protein but not the N protein. Moreover, children with and without MIS-C had reduced neutralizing activity as compared to both adult COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children independent of whether they develop MIS-C, with implications for developing age-targeted strategies for testing and protecting the population.
 
Back
Top Bottom